Xvivo Perfusion makes organ perfusion systems, the XVIVO Heart Assist Transport and Liver Assist devices, that keep donor hearts and livers alive outside the body for longer and under better conditions before transplant. The moat is a combination of clinical data, regulatory approvals in the US and EU, and a single-use disposable model that recurs with each transplant. Revenue growth of 34.0% and a 72.3% gross margin show the franchise is scaling, though the 10.5% operating margin says most of that gross profit is still being reinvested. The stock trades at 79.2x trailing and 37.8x forward earnings, so the case rests on margin expansion as volumes grow, and a PM should look hard at the cadence of operating leverage and the pace of US adoption before anything else.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 11:04 CEST | Fair value | kr 78.31 | first publication | kr 223 |
| 23 Oct 2026, 11:04 CEST | Rating | Overvalued | first publication | kr 223 |
| 23 Oct 2026, 01:52 CEST | ACCE price target | kr 207 | first publication | kr 223 |
Answered from Xvivo Perfusion AB (publ) fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| XVIVO.ST Xvivo Perfusion AB (publ) | kr 206.00 | kr 78 | 163% above | 73.0x | 4.1% | 66 | 57 |
| MCAP.ST MedCap AB (publ) | kr 600.50 | kr 385 | 56% above | 34.1x | 16.4% | 68 | 67 |
| VITR.ST Vitrolife AB (publ) | kr 108.80 | kr 111 | 2% below | - | -46.5% | 56 | 39 |
| NOLA-B.ST Nolato AB (publ) | kr 55.40 | kr 42 | 32% above | 20.8x | 13.1% | 64 | 51 |
| EKTA-B.ST Elekta AB (publ) | kr 57.60 | kr 51 | 13% above | - | -4.3% | 39 | 51 |
| GN.CO GN Store Nord | kr 112.10 | kr 102 | 10% above | - | 2.1% | 37 | 46 |
| AMBU-B.CO Ambu A/S | kr 79.30 | - | - | - | 0.0% | 50 | 37 |
Where XVIVO.ST ranks against its sector peers on each metric.